GSK moves its mRNA flu vaccine into late-stage trials after promising mid-stage results
A dual-protein approach sets GSK's candidate apart from Moderna's recently approved shot, and the race to redefine flu vaccination is now very much on
Dyson’s CameraJet toothbrush uses AI and a built-in camera to find and flush plaque...
Six years in development, the CameraJet combines a macro lens, machine learning, and a precision fluid jet — all in one device
Zaina launches Arabic-language AI assistant for aesthetic medicine in Saudi Arabia and Qatar
The platform has been operating across the Kingdom and Qatar since the summer, used by thousands of people considering procedures...
UK scientists to build a living library of human mini-organs
A £20m Cambridge research hub will grow organoids from NHS patient cells to improve drug testing and cut animal use
Who’s really in charge when AI enters the exam room?
A new AMA framework keeps physicians at the center of AI-enabled care — but a growing body of opinion is starting to ask whether that assumption still holds
London launches AI regulatory sandbox to fast-track medical devices into the NHS
A new programme from the MHRA and NHS England puts AI medical devices into live clinical settings, with oversight built in from the start
More than half the world would use AI for mental health support, new survey...
A large global study reveals striking public trust in ChatGPT-style tools for counselling, friendship, and even medical advice — but researchers are urging caution
FDA clears Roche’s pTau217 blood test for Alzheimer’s amyloid assessment in primary and specialty...
A single blood draw could now replace costly imaging for millions of patients who never make it to a neurologist
Aily Labs lists on Google Cloud Marketplace, targeting pharma and biotech
The decision intelligence platform can now be deployed inside Gemini Enterprise with no new vendor process or compliance review
Moderna and Merck’s personalized cancer vaccine hits its Phase 3 target in melanoma
A positive late-stage trial result for mRNA-based cancer immunotherapy sends Moderna's stock up nearly 150% — and raises real questions about what comes next for oncology